{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:16:48Z","timestamp":1779106608995,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.colsurfb.2026.115661","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:50:36Z","timestamp":1775231436000},"page":"115661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Loteprednol etabonate nanostructured lipid carriers for enhanced ocular bioavailability"],"prefix":"10.1016","volume":"264","author":[{"given":"Suraj","family":"Fanse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellen","family":"Maurus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Bhorkade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane J.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2026.115661_bib1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/1120672120929958","article-title":"Cataract surgery and dry eye disease: a review","volume":"30","author":"Naderi","year":"2020","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08830180212066","article-title":"Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy","volume":"21","author":"Stein-Streilein","year":"2002","journal-title":"Int Rev. Immunol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/pharmaceutics4020252","article-title":"Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems","volume":"4","author":"Occhiutto","year":"2012","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115661_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.18240\/ijo.2022.05.20","article-title":"Inflammation and dry eye disease-where are we?","volume":"15","author":"Rao","year":"2022","journal-title":"Int J. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00055735-200102000-00002","article-title":"Control of intra-ocular inflammation associated with cataract surgery","volume":"12","author":"El-Harazi","year":"2001","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0886-3350(97)80286-6","article-title":"Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension","volume":"23","author":"Assil","year":"1997","journal-title":"J. Cataract Refract Surg."},{"key":"10.1016\/j.colsurfb.2026.115661_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bjo.2007.132621","article-title":"Treatment of ocular inflammatory conditions with loteprednol etabonate","volume":"92","author":"Pavesio","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cvsm.2003.12.007","article-title":"The use of corticosteroids to treat ocular inflammation","volume":"34","author":"Holmberg","year":"2004","journal-title":"Vet. Clin. North Am. Small Anim. Pr."},{"key":"10.1016\/j.colsurfb.2026.115661_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10792-012-9589-2","article-title":"Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use","volume":"32","author":"Amon","year":"2012","journal-title":"Int Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib10","first-page":"177","article-title":"E. Davis, Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery","volume":"5","author":"Comstock","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib11","first-page":"1480","article-title":"Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation","volume":"24","author":"Stewart","year":"1998","journal-title":"Loteprednol Etabonate Post-Oper. Inflamm. Study Group 1 J. Cataract Refract Surg."},{"key":"10.1016\/j.colsurfb.2026.115661_bib12","first-page":"1780","article-title":"A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation","volume":"105","author":"Trial","year":"1998","journal-title":"Loteprednol Etabonate Postoper. Inflamm. Study Group 2 Ophthalmol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2016.10.009","article-title":"Lipid nanoparticles (SLN, NLC): overcoming the anatomical and physiological barriers of the eye \u2013 Part I \u2013 Barriers and determining factors in ocular delivery","volume":"110","author":"S\u00e1nchez-L\u00f3pez","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib14","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1080\/10717544.2016.1223225","article-title":"Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2026.115661_bib15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/jps.2600660905","article-title":"Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine","volume":"66","author":"Sieg","year":"1977","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2026.115661_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11095-018-2513-3","article-title":"Perspectives on physicochemical and in vitro profiling of ophthalmic ointments","volume":"35","author":"Bao","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.colsurfb.2026.115661_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119381","article-title":"Physicochemical attributes of white petrolatum from various sources used for ophthalmic ointment formulations","volume":"583","author":"Bao","year":"2020","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijpharm.2017.03.039","article-title":"Physicochemical attributes and dissolution testing of ophthalmic ointments","volume":"523","author":"Bao","year":"2017","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114867","article-title":"Non-aqueous formulations in topical ocular drug delivery \u2013 A paradigm shift?","volume":"198","author":"Agarwal","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115661_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.01.057","article-title":"Advances and limitations of drug delivery systems formulated as eye drops","volume":"321","author":"Jumelle","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115661_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"A.K. Mitra, Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090460","article-title":"Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents","volume":"11","author":"Souto","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115661_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071952","article-title":"A new era in ocular therapeutics: advanced drug delivery systems for uveitis and neuro-ophthalmologic conditions","author":"Wu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115661_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2019.01.018","article-title":"Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis","volume":"296","author":"Luo","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2026.115661_bib26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.molmed.2020.12.001","article-title":"Avoiding a sticky situation: bypassing the mucus barrier for improved local drug delivery","volume":"27","author":"Zierden","year":"2021","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.colsurfb.2026.115661_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115661_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17425247.2023.2181332","article-title":"Mucoadhesive drug delivery systems: a promising noninvasive approach to bioavailability enhancement. Part II: formulation considerations","volume":"20","author":"Kulkarni","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2026.115661_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425247.2023.2181331","article-title":"Mucoadhesive drug delivery systems: a promising non-invasive approach to bioavailability enhancement. Part I: biophysical considerations","volume":"20","author":"Kulkarni","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.colsurfb.2026.115661_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/nano9010033","article-title":"In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies","volume":"9","author":"Tatke","year":"2018","journal-title":"Nanomaterials"},{"key":"10.1016\/j.colsurfb.2026.115661_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ph16071001","article-title":"Ocular delivery of bimatoprost-loaded solid lipid nanoparticles for effective management of glaucoma","author":"Satyanarayana","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.colsurfb.2026.115661_bib32","article-title":"Lipid-based nanocarriers for ocular drug delivery: an updated review","volume":"76","author":"Das","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib33","article-title":"Development and optimization of ofloxacin as solid lipid nanoparticles for enhancement of its ocular activity","volume":"72","author":"Alhakamy","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/nano11010173","article-title":"Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery","volume":"11","author":"Khiev","year":"2021","journal-title":"Nanomater. (Basel)"},{"key":"10.1016\/j.colsurfb.2026.115661_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/0250-474X.57282","article-title":"Solid lipid nanoparticles: a modern formulation approach in drug delivery system","volume":"71","author":"Mukherjee","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2026.115661_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061593","article-title":"Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review","volume":"15","author":"Viegas","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115661_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijpharm.2015.09.014","article-title":"Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach","volume":"495","author":"Makwana","year":"2015","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","article-title":"Nanostructured lipid matrices for improved microencapsulation of drugs","volume":"242","author":"M\u00fcller","year":"2002","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib39","series-title":"Biodrug Delivery Systems","first-page":"187","article-title":"Ocular drug delivery systems: transscleral drug delivery to the posterior eye segment","author":"Urtti","year":"2010"},{"key":"10.1016\/j.colsurfb.2026.115661_bib40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2026.115661_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.07.017","article-title":"A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers","volume":"363","author":"Li","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/10717544.2022.2048134","article-title":"Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study","volume":"29","author":"Luo","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2026.115661_bib43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/10717544.2022.2048134","article-title":"Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study","volume":"29","author":"Luo","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2026.115661_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11120679","article-title":"Design and optimization of nanostructured lipid carrier containing dexamethasone for ophthalmic use","author":"L. Kiss","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.colsurfb.2026.115661_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jddst.2016.03.009","article-title":"A novel cationic nanostructured lipid carrier for improvement of ocular bioavailability: design, optimization, in vitro and in vivo evaluation","volume":"33","author":"Liu","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4155\/tde-2017-0088","article-title":"Recent advances in topical nano drug-delivery systems for the anterior ocular segment","volume":"9","author":"Lakhani","year":"2018","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.colsurfb.2026.115661_bib47","article-title":"Loteprednol loaded nanoformulations for corneal delivery: ex-vivo permeation study, ocular safety assessment and stability studies","volume":"81","author":"Uner","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030474","article-title":"Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms","author":"Gugleva","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.colsurfb.2026.115661_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/bios11040097","article-title":"Multi-functionalized nanomaterials and nanoparticles for diagnosis and treatment of retinoblastoma","volume":"11","author":"Arshad","year":"2021","journal-title":"Biosensors"},{"key":"10.1016\/j.colsurfb.2026.115661_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijpharm.2015.07.048","article-title":"Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation","volume":"493","author":"Beg","year":"2015","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.colsurfb.2017.03.006","article-title":"Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability","volume":"154","author":"Kaithwas","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115661_bib52","doi-asserted-by":"crossref","first-page":"e64094","DOI":"10.1371\/journal.pone.0064094","article-title":"Retinal pigmented epithelial cells cytotoxicity and apoptosis through activation of the mitochondrial intrinsic pathway: role of indocyanine green, brilliant blue and implications for chromovitrectomy","volume":"8","author":"Penha","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.colsurfb.2026.115661_bib53","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/toxres\/tfaa066","article-title":"Investigating the ocular toxicity potential and therapeutic efficiency of in situ gel nanoemulsion formulations of brinzolamide","author":"Talaei","year":"2020","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.colsurfb.2026.115661_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125834","article-title":"Mucoadhesive in situ forming gels: bridging Formulation design and physiological Realities","volume":"681","author":"Kulkarni","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2018.03.003","article-title":"In vitro and ex vivo correlation of drug release from ophthalmic ointments","volume":"276","author":"Bao","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.colsurfb.2026.115661_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/tvst.14.10.28","article-title":"Optimized protocol for isolation and culture of primary human corneal epithelial cells","volume":"14","author":"Yan","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1021\/acs.chemrestox.3c00339","article-title":"Cell via cell viability assay changes cellular metabolic characteristics by intervening with glycolysis and pentose phosphate pathway","volume":"37","author":"Fan","year":"2024","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.colsurfb.2019.01.018","article-title":"Penetration of Nile red-loaded nanostructured lipid carriers (NLCs) across the porcine cornea","volume":"176","author":"Niamprem","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.colsurfb.2026.115661_bib59","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2018.05.007","article-title":"Effect of formulation and process variables on lipid based sustained release tablets via continuous twin screw granulation: a comparative study","volume":"121","author":"Kallakunta","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2026.115661_bib60","first-page":"1049","article-title":"Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats","volume":"9","author":"Zhang","year":"2014","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.colsurfb.2026.115661_bib61","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcis.2017.07.008","article-title":"Effect of surfactant concentration and solidification temperature on the characteristics and stability of nanostructured lipid carrier (NLC) prepared from rambutan (Nephelium lappaceum L.) kernel fat","volume":"505","author":"Witayaudom","year":"2017","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.colsurfb.2026.115661_bib62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.colsurfa.2016.09.074","article-title":"Assessing the stability of Tween 80-based O\/W emulsions with cyclic voltammetry and electrical impedance spectroscopy","volume":"511","author":"Roldan-Cruz","year":"2016","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.colsurfb.2026.115661_bib63","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1021\/mp400154a","article-title":"Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis method","volume":"10","author":"Modi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib64","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s13346-013-0129-z","article-title":"In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challenges","volume":"3","author":"Shen","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.colsurfb.2026.115661_bib65","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2016.10.015","article-title":"Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues","volume":"109","author":"Balguri","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1211\/jpp.58.1.0006","article-title":"Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes","volume":"58","author":"Liu","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.colsurfb.2026.115661_bib67","series-title":"Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Modification of the Stratum Corneum","first-page":"195","article-title":"Transcutol\u00ae (Diethylene Glycol Monoethyl Ether): A Potential Penetration Enhancer","author":"Javadzadeh","year":"2015"},{"key":"10.1016\/j.colsurfb.2026.115661_bib68","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1124\/jpet.119.256446","article-title":"Gellan gum based sol-to-gel transforming system of natamycin transfersomes improves topical ocular delivery","volume":"370","author":"Janga","year":"2019","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.colsurfb.2026.115661_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125834","article-title":"Mucoadhesive in situ forming gels: bridging formulation design and physiological Realities","volume":"681","author":"Kulkarni","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115661_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11070321","article-title":"Penetration enhancers in ocular drug delivery","volume":"11","author":"Moiseev","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.colsurfb.2026.115661_bib71","article-title":"Opthalmic suspension composition, european patent specification","author":"Shawer","year":"2015","journal-title":"Int. Appl. Number PCT\/US2016\/014872"},{"key":"10.1016\/j.colsurfb.2026.115661_bib72","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.colsurfb.2026.115661_bib73","article-title":"Structure-centered design of lipid-based nanocarriers to overcome biological barriers","volume":"35","author":"Woo","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.colsurfb.2026.115661_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/263604","article-title":"Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives","volume":"2014","author":"Sahoo","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.colsurfb.2026.115661_bib75","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res"}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526002493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526002493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:52:55Z","timestamp":1779105175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":75,"alternative-id":["S0927776526002493"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115661","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loteprednol etabonate nanostructured lipid carriers for enhanced ocular bioavailability","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115661"}}